Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ad5NULL-A20.FCU1 + Flucytosine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ad5NULL-A20.FCU1 | Ad5NULL-A20.FCU1 is a replication-deficient adenovirus engineered to contain a peptide that binds ITGB6 (integrin alphaVbeta6) and to express FCU1, a bifunctional chimeric protein of CD and UPRTase that converts the prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU) and 5-fluorouridine monophosphate (5-FUMP), which potentially induces toxicity against tumor cells expressing ITGB6 (integrin alphaVbeta6) and inhibits tumor growth (PMID: 39369056). | |||
| Flucytosine | Ancobon | 5-FC |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|